3.86 USD
▼-0.02-0.52%
盘后 3.96 +2.59%
2026-09-15
市值
$903.84M
市盈率
—
EPS
-2.23
股息率
—
52 周区间
3.35 – 7.98
成交量
2.63M
Beta
0.92
目标价
14.62
52W 低 3.3552W 高 7.98
价格走势
公司简介
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...